Acylguanidine derivative or salt thereof
US8076348B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2006 |
| Grant date | Dec 13, 2011 |
| Priority date | — |
| Expiry date | Sep 1, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
[Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine.[Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.